Hai zheng selling stake to fill the huge loss 4 class 1 new drugs can be redeemed?

May 12 (UPI) -- Since the break-up between Hai and Pfizer in 2017, the company's net profit loss of nearly 500 million yuan in 2018 was the biggest since the company went public, with a large revenue loss, coupled with a blocked export of raw materials, a sharp drop in high-grossing product salesIn 2019, Hai is constantly selling assets to protect their lives, it is not easy to the first three quarters of net profit reached nearly 1.3 billion, but repeatedly charged asset impairment ..Haizheng Pharmaceuticals has been seeking transformation, in September 2019, the alliance collection, January 2020 national collection, the new crown epidemic under the first imitation of the Fabiriver film, etchave stimulated the share price, so in 2020 what other heavy products can help it to pull the momentum?Table 1: 2019 to date, Haizheng Pharmaceutical's performancesource: The company's annual reportin recent years, Haizheng Pharmaceutical's operating income has been a good achievement, but the net profit has always been unsatisfactory, in 2018 a huge loss of nearly 500 million, became the first time since the listingHaizheng Pharmaceuticals in the 2018 annual report mentioned that the realization of operating income decreased by 3.63% YoY, mainly due to the two-vote system after the comprehensive promotion, Hanyu Pharmaceutical's original RuihaiPfizer's product re-sales business into Pfizer direct sales, Hanyu Pharmaceuticals to do promotional business, reflected in the report revenue reduction and the provincial pharmaceutical company distribution and raw materials business declineThe loss in net profit was mainly due to the year-on-year decline in the gross profit of API sales, the suspension or suspension of development of some research and development capitalization projects, and the significant reduction of non-operating income due to the absence of Pfizer compensation income in the current yearTable 2: 2019 Haizheng Pharmaceutical "sell assets" part of the major eventssource: the company announced
that 2019 is the company's "reform year", in order to achieve a turn-around profit, Haizheng Pharmaceuticals put forward the "focus, slimming, optimization" three principles, the past year also active action, the introduction of strategic investment, speed up restructuring, disposal of some non-business related to the main industry, low income, year after year of loss of non-core business assets and assets idlethe first three quarters of 2019, Haizheng Pharmaceuticals continued to sell houses, sell equity, return funds more than 4 billion, and even sold 23 peacocks profit 15,000 yuan, all kinds of additional holdings, the first three quarters of the net profit rushed to 1.255 billion yuan, an increase of 17542 percent year-on-yearShareholders see victory in sight, how to know "one night back to the liberation."December 11, 2019, Haizheng Pharmaceuticals issued a notice to charge the impairment provisions of intangible assets related to outsourcing technology of 102 million yuan, the company's construction projects, fixed assets to take assets impairment provisions of 941 million yuan, inventory reduction provisions of 274 million yuan, a total increase of 1.3 billion yuanOn the other hand, also transferred 412 million yuan to research and development project development expenditure April 30, 2020, Haizheng Pharmaceuticals issued a notice, due to the suspension of a number of research and development projects, related capitalization expenditure needs to be transferred to the cost processing, the total amount of 5498.05 million yuan; Value of 29.4541 million yuan, impairment of fixed assets of 208.893 million yuan and impairment of 525.85 million yuan in construction works, according to the company holds 68% of the shares of Yunsheng Company, the above-mentioned asset impairment provisions of the net profit of the company's home income of 64.2807 million yuan audited by the accounting firm, the company confirmed that in 2019 the development expenditure was transferred to a cost-to-expense processing of 470 million yuan and the impairment provision of the assets charged was 1.46 billion yuan, reducing the company's net profit for 2019 and the owner's equity attributable to the shareholders of the parent company All along, the API business is one of the main business of Haizheng Pharmaceuticals, 80% of its revenue from overseas markets, in recent years by the United States FDA and the European Union EMA on the impact of the company's import ban on products, resulting in some exports to the United States, the European Union and other pharmaceutical market API reduction, operating income from 1,768 million yuan in 2014 to 1,359 million yuan in 2019 After saying goodbye to Pfizer, Haizheng Pharmaceuticals began to focus on the strategic layout of the domestic preparation business, and strive to achieve the transformation from a pharmaceutical company dominated by API to a comprehensive international brand pharmaceutical company Table 3: Products approved by Haizheng Pharmaceuticals source: Minet MED China Drug Review Database 2.0
Haizheng Pharmaceuticals' Adamu mono-resistance injection for therapeutic biologics 2 new drugs, will be included in the priority review in February 2019, and will be approved for production in December 2019 Minet data show that in 2019 in China's urban public , county-level public hospitals, urban community centers and township health hospitals (referred to as China's public medical institutions) terminal, Adamu single-resistant injection sudrin sales rose to 90 million yuan, AbbVie accounted for nearly 90%, domestic pharmaceutical companies Baiai Biopharmaceutical and Haizheng Biopharmaceutical accounted for 6.69%, 3.55% respectively the new tablets of succinic acid solina are suitable for the treatment of urinary incontinence and/or frequent urinary and urinary symptoms associated with patients with overactive bladder Minet data show that in 2019 in China's public medical institutions terminal, the sales of new tablets of succinic acid Solina in about 63 million yuan, Astellas Pharmaceuticals accounted for more than 99%, three of the domestic pharmaceutical companies received approval, Qilu Pharmaceuticals, Sichuan State Pharmaceuticals and Haizheng Pharmaceuticals are approved according to 4 categories of generics, as the same as the evaluation In the second round of national harvest in January 2010, three domestic pharmaceutical companies won the bid, Haizheng Pharmaceuticals won Beijing, Jiangsu, Shandong and other 10 provinces and cities 2020 to start the spring of the domestic new crown epidemic is serious, the first fapilave piece approved news suddenly blew up the pot Haizheng Pharmaceuticals' Fabirazave tablets 3 generic conditions approved production, after listing will continue to complete pharmacological and clinical pharmacological related research, and then to the national review bodies in a timely manner to report the results of the study, approved indications for the treatment of adult sashimi new or re-epidemic influenza (only for other anti-flu virus drug treatment is ineffective or ineffective) At the same time, Haizheng Pharmaceuticals obtained the clinical approval of the new coronavirus pneumonia indications of the Fabiravir tablets consistency evaluation, so far, Haizheng Pharmaceuticals has a total of 9 products through or regardas the same evaluation Ebeshatan tablets, Ruishuvastatin calcium tablets in 2017, 2018, the first round of the National Harvesting Alliance area expansion stage in September 2019, The Ozhushatan tablets won the bid in Hubei, Yunnan, Shanxi and other 9 provinces and cities, Ruishuvastatin calcium tablets won the bid shandong, Henan, Hubei and other 9 provinces and cities Minet data show that in China's public medical institutions terminal Ebesatan tablet sales of more than 2.5 billion yuan, subsidiary Hanyu Pharmaceutical's market share remained at about 4%, Ruishuvastatin calcium tablets sales of more than 6.2 billion yuan, Haizheng Pharmaceuticals market share increased from 2.08 percent in 2018 to 2.93 percent in 2019 an tablets in China in 2019 terminal sales of 1.3 billion, is the end-of-life treatment drug heavy products, the current number of evaluation enterprises has reached 3, whether the product will be included in the next round of national collection list, worthy of attention Table 4: 2019 Haizheng Pharmaceutical Spending (unit: 10,000 yuan) source: The company announced
that haizheng Pharmaceutical's total research and development investment in 2019 was 814 million yuan, accounting for 7.35% of operating income, down 21.31% YoY In terms of proportion, research and development investment in biopharmaceuticals accounted for 2.89% of revenue, but in terms of growth, innovative drugs increased by 12.62% year-on-year Table 5: 2019-present Haizheng Pharmaceuticals in the review of the listing application
source: Minet MED China Drug Review Database 2.0
injection ZL-2401 toluene for the joint declaration of Haizheng Pharmaceutical suth and re-ding class 1 new drugs, for anti-tumor drugs, in February 2020 by CDE, in April was included in the review and approval, is currently in the review and approval 1 new drug Heizer mabu for the treatment of primary hypercholesterolemia, the current foreign market has the same role target of the drug according to the wheat cloth in 2006 approved to enter the Chinese market In 2019, the global sales of McPhee will be approximately US$590 million, while the terminal sales of public medical institutions in China will be RMB510 million Haize Mab of Haizheng Pharmaceuticals was included in the priority review in March 2019 and is currently in the process of review and approval Mendong Insulin was developed by Novo Nordisk, listed in Europe in 1999, listed in the United States in 2000, entered the Chinese market in 2002, with global sales of DKK 18.1 billion (approximately US$2.3 billion) in 2019 and end-of-life sales of 1.4 billion yuan in public medical institutions in China At present, the domestic market has no domestic door winter insulin injection listed, in addition to Haizheng Pharmaceuticals, there are Ganli Pharmaceuticals, Tonghua Dongbao, Zhuhai Federal Pharmaceuticals listing application in the review and approval generics, the lulasione hydrochloric acid tablets are expected to hit the top, and Howson's four generic listing applications are also under review and approval The product is a new atypical antipsychotic, which was approved by the FDA in October 2010 to treat schizophrenia Table 6: Haizheng Pharmaceuticals 2020 plans to carry out research and development of new drugs source: the company announced that HS234 tablets is an oral selective estrogen receptor subtone, its main indications are estrogen receptor-positive, HER2-negative advanced breast cancer, in clinical drug compliance is better than the listed only injectable form of selective estrogen receptor subtones Fluorovis group injection is currently the only estrogen receptor sub-tone approved at home and abroad, in 2019 in China's public medical institutions terminal sales of more than 500 million yuan Haizheng Pharmaceuticals' insulin glargine injections were approved for clinical trial in 2017 and are expected to be reported for delivery in 2020 In 2019, at the end of China's public medical institutions, insulin sementoid injection sales exceeded 3.8 billion yuan, the current domestic brand has been Approved by Zhuhai Federal Pharmaceuticals In the first quarter of 2020, sales revenue affected by the outbreak declined, with Haizheng Pharmaceuticals' operating income of RMB2,499 million, down 10.66 percent YoY, and net profit loss of RMB71.41 million, down 325 percent YoY Haizheng Pharmaceuticals said that in 2020 the company clearly stated that the main task is "management promotion year", management operating target is set for operating income (consolidated number) of 11.5 billion yuan, a year-on-year increase of 3.9% source: Company's annual report, rice net database review data statistics as of May 9, 2020, if there is a mistake, please point in.